The Oncologist Community (@TOncologist) header
The Oncologist Community (@TOncologist) profile picture

Oncology online community. Dedicated to sharing experience and best practices. #oncology #MedTwitter

Joined July 2020
Photo by The Oncologist Community (@TOncologist)
The Oncologist Community retweeted
Molecular classification of renal cancer (7 groups). 1+2=angiogenesis (PBRM1 rich). 3+4 = immune and cell cycle rich. Group 5 +6 proliferative (p53 CDK2NA) = new therapies needed . Personalised randomised trials are possible.
3
39
6
135
The Oncologist Community retweeted
Congrats @florian_krammer and all the @IcahnMountSinai for this great paper! @OncoAlert
#SARSCoV2_Vaccines in Development | Mucosal and Systemic Responses | Florian Krammer @IcahnMountSinai @Nature buff.ly/2S9IScA | #2020_ReCapOct
4
11
The Oncologist Community retweeted
1) Only for t(11;14), consider + PI 2) A t(11;14) at diagnosis should be canonical - if (-) at relapse, ven should act similarly. 3) Consider an azole & halve the dose of ven. 4) Be ready for a rapid response (weeks) 5) Responses wane (~1 year) - what's the next step? #mmsm
2
3
1
11
The Oncologist Community retweeted
Final results of KROG0806: IMNI in node positive BC (presented by @hkbyun_ at 2020 KOSRO). First rad_onc multicenter ph3 RCT in Korea. So proud of Chang-ok Suh (PI) and Yong Bae Kim, my mentors for conducting this trial for 12 years from scratch. 👍👏🙏
7
16
5
60
The Oncologist Community retweeted
Simplified algorithm for stage 4 NSCLC, feedback appreciated.
9
2
22
The Oncologist Community retweeted
ENHERTU/Trastuzumab deruxtecan Granted Priority Review in the U.S. for Treatment of HER2 Positive Metastatic Gastric Cancer. Good to have more treatment options ! #stomachcancer #FDA daiichisankyo.com/media/pres…
4 months after ASCO and NEJM publication, Trastuzumab deruxtecan is approved for HER2 positive gastric cancer in Japan. Great news for us and our patients. I really appreciate all participants for the trial. daiichisankyo.com/media_inve… #gastric #cancer #HER2 #Trastuzumab #ASCO #ADC
4
9
2
41
The Oncologist Community retweeted
🚨⭐️Just in👉Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies @myESMO @ESMO_Open @notahedge esmoopen.bmj.com/content/5/5…
1
26
7
74
The Oncologist Community retweeted
Adding radiotherapy to immunotherapy improves OS and doubles out-of-field "abscopal" responses in #NSCLC. https://teapawt.net/t.co/Aka79WnNja. Our tumor agnostic Belgian CHEERS-trial (https://teapawt.net/t.co/L0YQg8F2uW) finished accrual today @komop_tgkanker. Let us hope we can confirm these findings
3
39
1
76
The Oncologist Community retweeted
Very elegant work from @decarvalho_lab @Pari_Mehdipour here in @nature suggesting that combining epigenetic therapies with ADAR1 inhibitors could be a promising cancer treatment. Could this strategy revive epigenetic therapies? nature.com/articles/s41586-0…
8
2
40
The Oncologist Community retweeted
We KNOW that the Geriatric Assessment is useful in oncology, AND guideline-recommended. But are people actually using it❓ The @ASCO #gerionc taskforce conducted a global survey which is now published in @ASCO_pubs JCO-OP. Check it out here 👇👇 ascopubs.org/doi/full/10.120…
3
38
3
80
The Oncologist Community retweeted
How radiation oncology is changing💡? 1.5 T MRlinac-guided SABR for isolated abdominal metastasis: check as never before radiation delivery on target 🎯 in high quality and in real time! #radonc #mrlinac #igrt #oligomets #adaptiveRT – at Verona, Veneto
8
49
4
190
The Oncologist Community retweeted
Spanish study finds higher mortality risk among myeloma patients hospitalized for COVID. @mvmateos #BCJ Blood Cancer Journal #WearAMask #StaySafe nature.com/articles/s41408-0…
1
21
2
34
The Oncologist Community retweeted
Routine drains not necessary in liver surgery – same as for pancreatic surgery Drain Placement After Uncomplicated Hepatic Resection Increases Severe Postoperative Complication Rate: A Japanese … pubmed.ncbi.nlm.nih.gov/3306…
2
8
1
19
The Oncologist Community retweeted
An important part of the informed consent process - outlining how long a “temporary stoma” may be temporary
New on Early View: Stoma reversal after intended restorative rectal cancer resection in Denmark: nationwide population‐based study ow.ly/wi4e30rdUVU
4
8
1
24
If you are a top expert in your field, you have a tremendous power to uplift early career people with just a few words of encouragement. After my #ESMO20 talk, I received an email from Prof Fatima Cardoso congratulating me on my talk. It meant so much to me. Some thoughts 1/
4
8
1
88
New precision therapy targeting DNA damage responses - @CD_AACR @AACR @royalmarsdenNHS @ICR_London First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors cancerdiscovery.aacrjournals…
1
9
2
24
Does anyone know the evidence behind aggressively checking and replacing potassium daily in hospitalized patients? It’s like 30% of what interns do so I imagine it must save millions of lives per year.
23
9
138